MA40993A - Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 - Google Patents
Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139Info
- Publication number
- MA40993A MA40993A MA040993A MA40993A MA40993A MA 40993 A MA40993 A MA 40993A MA 040993 A MA040993 A MA 040993A MA 40993 A MA40993 A MA 40993A MA 40993 A MA40993 A MA 40993A
- Authority
- MA
- Morocco
- Prior art keywords
- gpr139
- modulators
- dihydro
- oxo
- compounds
- Prior art date
Links
- DMSSTTLDFWKBSX-UHFFFAOYSA-N 1h-1,2,3-benzotriazin-4-one Chemical class C1=CC=C2C(=O)N=NNC2=C1 DMSSTTLDFWKBSX-UHFFFAOYSA-N 0.000 title 1
- 101000996780 Homo sapiens Probable G-protein coupled receptor 139 Proteins 0.000 title 1
- 102100033836 Probable G-protein coupled receptor 139 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne un procédé permettant de traiter une maladie, un trouble ou un état pathologique associé à gpr139 à l'aide de composés de formule 1, lesquels composés sont des agonistes de gpr139, certains composés représentés par la formule 1, des compositions pharmaceutiques de ceux-ci, des procédés de fabrication desdits composés, et des intermédiaires de ceux-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082539P | 2014-11-20 | 2014-11-20 | |
| US201562184729P | 2015-06-25 | 2015-06-25 | |
| PCT/US2015/061607 WO2016081736A1 (fr) | 2014-11-20 | 2015-11-19 | 4-oxo-3,4-dihydro-1,2,3-benzotriazines utilisées en tant que modulateurs de gpr139 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40993A true MA40993A (fr) | 2017-09-27 |
| MA40993B1 MA40993B1 (fr) | 2019-07-31 |
Family
ID=55022667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40993A MA40993B1 (fr) | 2014-11-20 | 2015-11-19 | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 |
Country Status (40)
| Country | Link |
|---|---|
| US (5) | US9556130B2 (fr) |
| EP (2) | EP3536324B1 (fr) |
| JP (2) | JP6637501B2 (fr) |
| KR (1) | KR102582021B1 (fr) |
| CN (2) | CN107108531B (fr) |
| AU (1) | AU2015349866B2 (fr) |
| CA (1) | CA2968242C (fr) |
| CL (1) | CL2017001292A1 (fr) |
| CO (1) | CO2017005959A2 (fr) |
| CR (1) | CR20170275A (fr) |
| CY (2) | CY1122613T1 (fr) |
| DK (2) | DK3221298T3 (fr) |
| DO (1) | DOP2017000120A (fr) |
| EA (1) | EA033728B1 (fr) |
| EC (1) | ECSP17038999A (fr) |
| ES (2) | ES2734735T3 (fr) |
| GE (2) | GEP20196961B (fr) |
| HR (2) | HRP20191003T1 (fr) |
| HU (2) | HUE057451T2 (fr) |
| IL (1) | IL252311B (fr) |
| JO (1) | JO3719B1 (fr) |
| LT (2) | LT3221298T (fr) |
| MA (1) | MA40993B1 (fr) |
| MD (1) | MD3221298T2 (fr) |
| MX (1) | MX378158B (fr) |
| MY (1) | MY187423A (fr) |
| NZ (1) | NZ732208A (fr) |
| PE (1) | PE20170899A1 (fr) |
| PH (1) | PH12017500920A1 (fr) |
| PL (2) | PL3221298T3 (fr) |
| PT (2) | PT3536324T (fr) |
| RS (2) | RS59078B1 (fr) |
| SG (1) | SG11201704002UA (fr) |
| SI (2) | SI3221298T1 (fr) |
| SM (2) | SMT201900355T1 (fr) |
| TN (1) | TN2017000196A1 (fr) |
| TW (1) | TWI684590B (fr) |
| UA (1) | UA120375C2 (fr) |
| UY (1) | UY36406A (fr) |
| WO (1) | WO2016081736A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
| US12042496B2 (en) | 2018-10-16 | 2024-07-23 | The University Of Florida Research Foundation, Incorporated | Methods related to opioid therapeutics |
| WO2020097609A1 (fr) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Modulateurs du récepteur gpr139 |
| AR119971A1 (es) | 2019-09-16 | 2022-01-26 | Takeda Pharmaceuticals Co | Derivados de piridazin-3(2h)-ona fusionados con azol |
| WO2021127459A1 (fr) * | 2019-12-20 | 2021-06-24 | Blackthorn Therapeutics, Inc. | Modulateurs du récepteur gpr139 |
| EP4146635A1 (fr) * | 2020-05-08 | 2023-03-15 | Takeda Pharmaceutical Company Limited | Métabolites de benzotriazinone substitués d'un agoniste gpr139 |
| TW202227087A (zh) * | 2020-09-21 | 2022-07-16 | 日商武田藥品工業股份有限公司 | 精神分裂症之治療 |
| US11760788B2 (en) | 2021-03-02 | 2023-09-19 | Pathways Neuro Pharma, Inc. | Neuroreceptor compositions and methods of use |
| CN116693545A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用 |
| CN116693536A (zh) * | 2022-03-01 | 2023-09-05 | 上海科技大学 | 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用 |
| CN117986183A (zh) * | 2022-10-28 | 2024-05-07 | 浙江友宁生物医药科技有限公司 | 一种gpr139受体激动剂、其制备方法及其应用 |
| WO2024102802A1 (fr) * | 2022-11-11 | 2024-05-16 | Takeda Pharmaceutical Company Limited | Zélatriazine pour le traitement de la dépression |
| WO2025119351A1 (fr) * | 2023-12-08 | 2025-06-12 | 深圳湾实验室 | Agoniste de gpr139 |
| WO2025162441A1 (fr) * | 2024-02-02 | 2025-08-07 | 上海科技大学 | Composés hétérocycliques fusionnés, leur procédé de préparation, compositions pharmaceutiques et leur utilisation |
| CN121159462A (zh) * | 2025-11-19 | 2025-12-19 | 杭州市第七人民医院(杭州市心理危机研究与干预中心) | 喹唑啉酮类化合物及其在制备神经系统疾病药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794726A (en) | 1972-08-21 | 1974-02-26 | Uniroyal Inc | Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one |
| US4959368A (en) | 1986-02-24 | 1990-09-25 | Mitsui Petrochemical Industries Ltd. | Therapeutic agent for neurological diseases |
| ATE108791T1 (de) * | 1987-11-04 | 1994-08-15 | Beecham Group Plc | Neue 4-oxobenzotriazine und 4-oxochinazoline. |
| CA2526506A1 (fr) | 2003-06-09 | 2004-12-16 | Boehringer Ingelheim International Gmbh | Inhibiteurs du papillomavirus |
| CA2533824A1 (fr) | 2003-07-31 | 2005-02-10 | Irm, Llc | Composes bicycliques et compositions utilisees comme inhibiteurs pdf |
| FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
| AR058705A1 (es) | 2005-12-23 | 2008-02-20 | Astrazeneca Ab | Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1) |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| MX2009010218A (es) * | 2007-03-23 | 2009-10-19 | Hoffmann La Roche | Derivados de aza-piridopirimidinona. |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2011138265A2 (fr) | 2010-05-03 | 2011-11-10 | Evotec Ag | Dérivés d'indole et d'indazole utilisés comme antagonistes du récepteur de l'orexine |
| JP2016515138A (ja) | 2013-03-14 | 2016-05-26 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｇｐｒ１３９の生理的リガンド |
| JO3719B1 (ar) * | 2014-11-20 | 2021-01-31 | Takeda Pharmaceuticals Co | 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139 |
-
2015
- 2015-11-18 JO JOP/2015/0282A patent/JO3719B1/ar active
- 2015-11-19 JP JP2017526844A patent/JP6637501B2/ja active Active
- 2015-11-19 AU AU2015349866A patent/AU2015349866B2/en active Active
- 2015-11-19 US US14/946,194 patent/US9556130B2/en active Active
- 2015-11-19 SM SM20190355T patent/SMT201900355T1/it unknown
- 2015-11-19 UY UY0001036406A patent/UY36406A/es not_active Application Discontinuation
- 2015-11-19 LT LTEP15816275.0T patent/LT3221298T/lt unknown
- 2015-11-19 LT LTEP19152036.0T patent/LT3536324T/lt unknown
- 2015-11-19 EA EA201791096A patent/EA033728B1/ru unknown
- 2015-11-19 MX MX2017006448A patent/MX378158B/es unknown
- 2015-11-19 EP EP19152036.0A patent/EP3536324B1/fr active Active
- 2015-11-19 HU HUE19152036A patent/HUE057451T2/hu unknown
- 2015-11-19 HR HRP20191003TT patent/HRP20191003T1/hr unknown
- 2015-11-19 RS RS20190776A patent/RS59078B1/sr unknown
- 2015-11-19 WO PCT/US2015/061607 patent/WO2016081736A1/fr not_active Ceased
- 2015-11-19 SI SI201530772T patent/SI3221298T1/sl unknown
- 2015-11-19 KR KR1020177016973A patent/KR102582021B1/ko active Active
- 2015-11-19 CN CN201580071393.8A patent/CN107108531B/zh active Active
- 2015-11-19 PT PT191520360T patent/PT3536324T/pt unknown
- 2015-11-19 UA UAA201705041A patent/UA120375C2/uk unknown
- 2015-11-19 NZ NZ732208A patent/NZ732208A/en unknown
- 2015-11-19 CA CA2968242A patent/CA2968242C/fr active Active
- 2015-11-19 DK DK15816275.0T patent/DK3221298T3/da active
- 2015-11-19 SM SM20220142T patent/SMT202200142T1/it unknown
- 2015-11-19 PE PE2017000866A patent/PE20170899A1/es unknown
- 2015-11-19 MD MDE20170117 patent/MD3221298T2/ro unknown
- 2015-11-19 MY MYPI2017701778A patent/MY187423A/en unknown
- 2015-11-19 HR HRP20212009TT patent/HRP20212009T1/hr unknown
- 2015-11-19 SG SG11201704002UA patent/SG11201704002UA/en unknown
- 2015-11-19 TN TN2017000196A patent/TN2017000196A1/en unknown
- 2015-11-19 SI SI201531729T patent/SI3536324T1/sl unknown
- 2015-11-19 PL PL15816275T patent/PL3221298T3/pl unknown
- 2015-11-19 DK DK19152036.0T patent/DK3536324T3/da active
- 2015-11-19 TW TW104138295A patent/TWI684590B/zh active
- 2015-11-19 RS RS20211398A patent/RS62563B1/sr unknown
- 2015-11-19 ES ES15816275T patent/ES2734735T3/es active Active
- 2015-11-19 ES ES19152036T patent/ES2897545T3/es active Active
- 2015-11-19 HU HUE15816275A patent/HUE044145T2/hu unknown
- 2015-11-19 CR CR20170275A patent/CR20170275A/es unknown
- 2015-11-19 PL PL19152036T patent/PL3536324T3/pl unknown
- 2015-11-19 CN CN202010988947.3A patent/CN112062730B/zh active Active
- 2015-11-19 GE GEAP201514515A patent/GEP20196961B/en unknown
- 2015-11-19 MA MA40993A patent/MA40993B1/fr unknown
- 2015-11-19 GE GEAP201814515A patent/GEAP201814515A/en unknown
- 2015-11-19 EP EP15816275.0A patent/EP3221298B1/fr active Active
- 2015-11-19 PT PT15816275T patent/PT3221298T/pt unknown
-
2016
- 2016-12-16 US US15/382,490 patent/US9770450B2/en active Active
-
2017
- 2017-05-12 DO DO2017000120A patent/DOP2017000120A/es unknown
- 2017-05-16 IL IL252311A patent/IL252311B/en active IP Right Grant
- 2017-05-18 PH PH12017500920A patent/PH12017500920A1/en unknown
- 2017-05-19 CL CL2017001292A patent/CL2017001292A1/es unknown
- 2017-06-16 CO CONC2017/0005959A patent/CO2017005959A2/es unknown
- 2017-06-20 EC ECIEPI201738999A patent/ECSP17038999A/es unknown
- 2017-08-22 US US15/683,589 patent/US10159677B2/en active Active
-
2018
- 2018-11-02 US US16/179,709 patent/US10561662B2/en active Active
-
2019
- 2019-06-20 CY CY20191100646T patent/CY1122613T1/el unknown
- 2019-12-20 JP JP2019229837A patent/JP6918088B2/ja active Active
-
2020
- 2020-01-02 US US16/732,536 patent/US11173161B2/en active Active
-
2021
- 2021-12-17 CY CY20211101111T patent/CY1124929T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40993A (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| MX388682B (es) | Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119. | |
| EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| EA201691514A1 (ru) | Соединения | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| MA40302A1 (fr) | Dérivés de carbazole | |
| CL2020001589A1 (es) | Proceso para la preparación de derivados de quinolina. | |
| BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
| MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| PE20160860A1 (es) | Derivados de etinil-imidazolidin-2,4-diona como moduladores de mglur 4 | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| MX2016011630A (es) | Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. | |
| MA46307B1 (fr) | Composition et procédés pour moduler l'expression du facteur b du complément | |
| MA35887B1 (fr) | Nouveaux dérivés morpholynyle utiles comme inhibiteurs de mogat-2 |